Search

Your search keyword '"Shapera, Shane"' showing total 222 results
Start Over Author "Shapera, Shane"
222 results on '"Shapera, Shane"'

1. The Clinical Frailty Scale for Risk Stratification in Patients With Fibrotic Interstitial Lung Disease

Author

Guler, Sabina A., Marinescu, Daniel-Costin, Cox, Gerard, Durand, Celine, Fisher, Jolene H., Grant-Orser, Amanda, Goobie, Gillian C., Hambly, Nathan, Johannson, Kerri A., Khalil, Nasreen, Kolb, Martin, Lok, Stacey, MacIsaac, Sarah, Manganas, Helene, Marcoux, Veronica, Morisset, Julie, Scallan, Ciaran, Shapera, Shane, Sun, Kelly, Zheng, Boyang, Ryerson, Christopher J., and Wong, Alyson W.

Published
2024
Full Text
View/download PDF

3. Characteristics and risk factors of interstitial pneumonia with autoimmune features

Author

Vahidy, Sana, Agyeman, Jonathan, Zheng, Boyang, Donohoe, Kathryn, Hambly, Nathan, Johannson, Kerri A., Assayag, Deborah, Fisher, Jolene H., Manganas, Helene, Marcoux, Veronica, Khalil, Nasreen, Kolb, Martin, Ryerson, Christopher J., Wong, Alyson W., Lok, Stacey, Morisset, Julie, Fell, Charlene D., Shapera, Shane, Gershon, Andrea S., Cox, Gerard, Halayko, Andrew J., Sadatsafavi, Mohsen, Wilcox, Pearce G., and To, Teresa

Published
2024
Full Text
View/download PDF

4. Integration and Application of Radiologic Patterns From Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis

Author

Marinescu, Daniel-Costin, Hague, Cameron J., Muller, Nestor L., Murphy, Darra, Churg, Andrew, Wright, Joanne L., Al-Arnawoot, Amna, Bilawich, Ana-Maria, Bourgouin, Patrick, Cox, Gerard, Durand, Celine, Elliot, Tracy, Ellis, Jennifer, Fisher, Jolene H., Fladeland, Derek, Grant-Orser, Amanda, Goobie, Gillian C., Guenther, Zachary, Haider, Ehsan, Hambly, Nathan, Huynh, James, Johannson, Kerri A., Karjala, Geoffrey, Khalil, Nasreen, Kolb, Martin, Leipsic, Jonathon, Lok, Stacey, MacIsaac, Sarah, McInnis, Micheal, Manganas, Helene, Marcoux, Veronica, Mayo, John, Morisset, Julie, Scallan, Ciaran, Sedlic, Tony, Shapera, Shane, Sun, Kelly, Tan, Victoria, Wong, Alyson W., Zheng, Boyang, and Ryerson, Christopher J.

Published
2023
Full Text
View/download PDF

6. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

Author

Haynes-Harp, Shana, Poli, Fernando, Vidya, Coimbatore Sree, Baron, Rebecca R., Clouser, Timothy, Doyle, Tracy, Maeda, Anthony, Highland, Kristin B., Albayda, Jemima F., Collins, Sarah E., Suresh, Karthik S., Davis, John M., Limper, Andrew H., Amigues, Isabel, Eliopoulos, Kristina, Swigris, Jeffery J., Humphries, Stephen, Huntwork, John C., Glynn, Chris, Duncan, Steve R., Danila, Maria I., Glassberg, Marilyn K., Oberstein, Elana M., Belloli, Elizabeth A., Briggs, Linda, Nagaraja, Vivek, Cholewa, Linda, DiFranco, Donna, Green, Edward, Liffick, Christie, Naik, Tanvi, Montas, Genevieve, Lebiedz-Odrobina, Dorota, Bissell, Reba, Wener, Mark, Lancaster, Lisa H., Crawford, Leslie J., Chan, Karmela, Kaner, Robert J., Morris, Alicia, Wu, Xiaoping, Khalidi, Nader A., Ryerson, Christopher J., Wong, Alyson W., Fell, Charlene D., LeClercq, Sharon A., Hyman, Mark, Shapera, Shane, Mittoo, Shikha, Shaffu, Shireen, Gaffney, Karl, Wilson, Andrew M., Barratt, Shaney, Gunawardena, Harsha, Hoyles, Rachel K., David, Joel, Kewalramani, Namrata, Maher, Toby M., Molyneaux, Philip L., Kokosi, Maria A., Cates, Matthew J., Mandizha, Mandizha, Ashish, Abdul, Chelliah, Gladstone, Parfrey, Helen, Thillai, Muhunthan, Vila, Josephine, Fletcher, Sophie V., Beirne, Paul, Favager, Clair, Brown, Jo, Dawson, Julie K., Ortega, Pilar Rivera, Haque, Sahena, Watson, Pippa, Khoo, Jun K., Symons, Karen, Youssef, Peter, Mackintosh, John A., Solomon, Joshua J, Danoff, Sonye K, Woodhead, Felix A, Hurwitz, Shelley, Maurer, Rie, Glaspole, Ian, Dellaripa, Paul F, Gooptu, Bibek, Vassallo, Robert, Cox, P Gerard, Flaherty, Kevin R, Adamali, Huzaifa I, Gibbons, Michael A, Troy, Lauren, Forrest, Ian A, Lasky, Joseph A, Spencer, Lisa G, Golden, Jeffrey, Scholand, Mary Beth, Chaudhuri, Nazia, Perrella, Mark A, Lynch, David A, Chambers, Daniel C, Kolb, Martin, Spino, Cathie, Raghu, Ganesh, Goldberg, Hilary J, and Rosas, Ivan O

Published
2023
Full Text
View/download PDF

7. Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease

Author

Comes, Alessia, Wong, Alyson W., Fisher, Jolene H., Morisset, Julie, Johannson, Kerri A., Farrand, Erica, Fell, Charlene D., Kolb, Martin, Manganas, Hélène, Cox, Gerard, Gershon, Andrea S., Halayko, Andrew J., Hambly, Nathan, Khalil, Nasreen, Sadatsafavi, Mohsen, Shapera, Shane, To, Teresa, Wilcox, Pearce G., Collard, Harold R., and Ryerson, Christopher J.

Published
2022
Full Text
View/download PDF

8. Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.

Author

Cheema, Parneet K., Iafolla, Marco A. J., Abdel-Qadir, Husam, Bellini, Andrew B., Chatur, Nazira, Chandok, Natasha, Comondore, Vikram R., Cunningham, Morven, Halperin, Ilana, Hu, Anne B., Jaskolka, Diana, Darvish-Kazem, Saeed, Khandaker, Masud H., Kitchlu, Abhijat, Sachdeva, Jasdip S., Shapera, Shane, Woolnough, Nicholas R. J., and Nematollahi, Massey

Subjects
DRUG side effects, IMMUNE checkpoint inhibitors, ADVERSE health care events, MEDICAL personnel, PATIENT care
Abstract

The increased use of immune checkpoint inhibitors (ICIs) across cancer programs has created the need for standardized monitoring and management of immune-related adverse events (irAEs). Delayed recognition without appropriate treatment can have serious and life-threatening consequences. The management of irAEs presents a unique set of challenges that must be addressed at a multidisciplinary level. Although various national and international guidelines and working groups provide high-level recommendations for the management of irAEs, practical guidance is lacking. Furthermore, timely collaboration between specialists requires institutional protocols that enable the early recognition, assessment, and treatment of irAEs. Such protocols should be developed by institution specialists and include algorithms for all healthcare providers involved in the care of patients treated with ICIs. At William Osler Health System in Brampton, Ontario, practical step-by-step multidisciplinary treatment approaches with recommendations for the management of irAEs were developed in collaboration with experts across Canada. Here, we provide an in-depth description of the approaches, outlining baseline investigations prior to the initiation of ICIs, as well as the monitoring and management of irAEs based on symptoms, severity, and involved organ systems. We encourage other centres to adapt and modify our approaches according to their specific needs and requirements. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study

Author

Adams, Colin J., Shapera, Shane, Ryerson, Christopher J., Assayag, Deborah, Johannson, Kerri A., Fell, Charlene D., Morisset, Julie, Manganas, Hélène, Kolb, Martin, Hambly, Nathan, Cox, Gerard, Khalil, Nasreen, Marcoux, Veronica, Wilcox, Pearce G., To, Teresa, Sadatsafavi, Mohsen, Halayko, Andrew J., Gershon, Andrea, Garlick, Kristopher, and Fisher, Jolene H.

Published
2022
Full Text
View/download PDF

11. Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi‐centre registry cohort

Author

Marcoux, Veronica, primary, Lok, Stacey D., additional, Mondal, Prosanta, additional, Assayag, Deborah, additional, Fisher, Jolene H., additional, Shapera, Shane, additional, Morisset, Julie, additional, Manganas, Hélène, additional, Fell, Charlene D., additional, Hambly, Nathan, additional, Cox, P. Gerard, additional, Kolb, Martin, additional, Gershon, Andrea S., additional, To, Teresa, additional, Sadatsafavi, Mohsen, additional, Khalil, Nasreen, additional, Wong, Alyson W., additional, Wilcox, Pearce G., additional, Ryerson, Christopher J., additional, Vu, Thao, additional, and Johannson, Kerri A., additional

Published
2024
Full Text
View/download PDF

12. Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease

Author

Adams, Colin J., Chohan, Karan, Rozenberg, Dmitry, Kavanagh, John, Greyling, Gerhard, Shapera, Shane, and Fisher, Jolene H.

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Corticosteroids -- Health aspects, Lung diseases -- Health aspects, Mortality -- Canada, CT imaging -- Health aspects, Diagnostic imaging -- Health aspects, Company business management, Health
Abstract

Background and Objective Despite the high mortality of acute exacerbations of interstitial lung disease (AE-ILD), there is minimal evidence to guide management decisions. We aimed to assess the feasibility and outcomes of a standardized management protocol for AE-ILD. Methods We performed a retrospective cohort study of patients with AE-ILD admitted to hospital between January 2015 and August 2019. Patients were managed with a standardized protocol including chest computed tomography (CT) at diagnosis, pulse corticosteroid treatment, and a follow-up CT 7 days after corticosteroid pulse. The association between idiopathic pulmonary fibrosis (IPF) versus non-IPF diagnosis and transplant-free survival within 1-year of AE-ILD was assessed using adjusted Cox proportional hazards regression survival analysis. Associations with CT chest improvement 7 days after corticosteroid pulse were secondarily assessed. Results 89 patients with AE-ILD were identified. 1-year transplant-free and overall survival were 20.2 and 51.7%, respectively. Protocol adherence to pulse corticosteroids was high (95.5%). A diagnosis of IPF was associated with higher risk of death or transplant at 1-year versus a non-IPF diagnosis [hazard ratio (HR) 2.23, 95% CI 1.19-4.17, p = 0.012]. There were no significant associations with 7-day CT improvement; however, CT improvement was associated with higher transplant-free survival (p = 0.02) and a lower risk of in-hospital mortality ([chi].sup.2 = 7.06, p = 0.01) on unadjusted analysis. Conclusions IPF is associated with a higher risk of death or transplant at 1-year as compared to a non-IPF diagnosis in patients with AE-ILD managed using a standardized protocol. Improvement on CT chest 7 days after corticosteroid pulse is associated with better survival., Author(s): Colin J. Adams [sup.1], Karan Chohan [sup.2], Dmitry Rozenberg [sup.1] [sup.3], John Kavanagh [sup.4], Gerhard Greyling [sup.4], Shane Shapera [sup.1], Jolene H. Fisher [sup.1] [sup.5] Author Affiliations: (1) grid.17063.33, [...]

Published
2021
Full Text
View/download PDF

15. Lung imaging patterns in connective tissue disease–associated interstitial lung disease impact prognosis and immunosuppression response

Author

Zheng, Boyang, primary, Marinescu, Daniel-Costin, additional, Hague, Cameron J, additional, Muller, Nestor L, additional, Murphy, Darra, additional, Churg, Andrew, additional, Wright, Joanne L, additional, Al-Arnawoot, Amna, additional, Bilawich, Ana-Maria, additional, Bourgouin, Patrick, additional, Cox, Gerard, additional, Durand, Celine, additional, Elliot, Tracy, additional, Ellis, Jennifer, additional, Fisher, Jolene H, additional, Fladeland, Derek, additional, Grant-Orser, Amanda, additional, Goobie, Gillian C, additional, Guenther, Zachary, additional, Haider, Ehsan, additional, Hambly, Nathan, additional, Huynh, James, additional, Johannson, Kerri A, additional, Karjala, Geoffrey, additional, Khalil, Nasreen, additional, Kolb, Martin, additional, Leipsic, Jonathon, additional, Lok, Stacey D, additional, MacIsaac, Sarah, additional, McInnis, Micheal, additional, Manganas, Helene, additional, Marcoux, Veronica, additional, Mayo, John, additional, Morisset, Julie, additional, Scallan, Ciaran, additional, Sedlic, Tony, additional, Shapera, Shane, additional, Sun, Kelly, additional, Tan, Victoria, additional, Wong, Alyson W, additional, and Ryerson, Christopher J, additional

Published
2024
Full Text
View/download PDF

16. Characteristics and risk factors of interstitial pneumonia with autoimmune features

Author

Vahidy, Sana, primary, Agyeman, Jonathan, additional, Zheng, Boyang, additional, Donohoe, Kathryn, additional, Hambly, Nathan, additional, Johannson, Kerri A., additional, Assayag, Deborah, additional, Fisher, Jolene H., additional, Manganas, Helene, additional, Marcoux, Veronica, additional, Khalil, Nasreen, additional, Kolb, Martin, additional, Ryerson, Christopher J., additional, Wong, Alyson W., additional, Lok, Stacey, additional, Morisset, Julie, additional, Fell, Charlene D., additional, Shapera, Shane, additional, Gershon, Andrea S., additional, Cox, Gerard, additional, Halayko, Andrew J., additional, Sadatsafavi, Mohsen, additional, Wilcox, Pearce G., additional, and To, Teresa, additional

Published
2023
Full Text
View/download PDF

17. Prognostic factors associated with mortality in acute exacerbations of idiopathic pulmonary fibrosis: A systematic review and meta-analysis

Author

Pitre, Tyler, primary, Lupas, Daniel, additional, Ebeido, Ibrahim, additional, Colak, Alexander, additional, Modi, Mihir, additional, Kachkovski, George V., additional, Montesi, Sydney B., additional, Khor, Yet H., additional, Kawano-Dourado, Leticia, additional, Jenkins, Gisli, additional, Fisher, Jolene H., additional, Shapera, Shane, additional, Rochwerg, Bram, additional, Couban, Rachel, additional, and Zeraatkar, Dena, additional

Published
2023
Full Text
View/download PDF

18. Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease

Author

Chen, Tao, Tsai, Amy Po Yu, Hur, Seo Am, Wong, Alyson W., Sadatsafavi, Mohsen, Fisher, Jolene H., Johannson, Kerri A., Assayag, Deborah, Morisset, Julie, Shapera, Shane, Khalil, Nasreen, Fell, Charlene D., Manganas, Helene, Cox, Gerard, To, Teresa, Gershon, Andrea S., Hambly, Nathan, Halayko, Andrew J., Wilcox, Pearce G., Kolb, Martin, and Ryerson, Christopher J.

Published
2021
Full Text
View/download PDF

20. Early versus late onset interstitial lung disease in rheumatoid arthritis: An observational study of risk factors and mortality in Ontario, Canada.

Author

Fidler, Lee, Widdifield, Jessica, Fisher, Jolene, Shapera, Shane, and Gershon, Andrea S.

Subjects
MORTALITY risk factors, RHEUMATOID arthritis, INTERSTITIAL lung diseases, THERAPEUTICS, SCIENTIFIC observation, DISEASE progression
Abstract

Background and Objective: Interstitial lung disease (ILD) can occur as a manifestation of rheumatoid arthritis (RA) at various times in the disease course. We aimed to identify factors associated with early versus late onset RA‐ILD and how the timing of RA‐ILD influenced surgical lung biopsy completion and mortality. Methods: We performed a retrospective observational study using health services data from Ontario, Canada. We identified RA cases between 2000 and 2020 using the Ontario Rheumatoid Arthritis Database. RA‐ILD diagnosis required repeat physician visits for ILD, with early RA‐ILD defined as within 1 year of RA diagnosis. We performed multivariable logistic regression to identify factors associated with early RA‐ILD and surgical lung biopsy completion, and multivariable cox‐proportional hazards regression to evaluate the association of early versus late RA‐ILD on all‐cause and RA‐ILD related mortality. Results: In total, we identified 3717 cases of RA‐ILD. Older age at RA diagnosis [OR 1.04 (95%CI 1.03–1.05), p < 0.0001], female sex [OR 1.16 (95%CI 1.01–1.35), p = 0.04] and immigrating to Ontario [OR 1.70 (95%CI 1.35–2.14), p < 0.0001] was associated with early RA‐ILD. Patients with early versus late RA‐ILD experienced similar odds of undergoing a surgical lung biopsy [OR 1.34 (95%CI 0.83–2.16), p = 0.23]. Early RA‐ILD was associated with increased all‐cause mortality [HR 1.17 (95%CI 1.07–1.29), p = 0.0009], primarily driven by an increase in RA‐ILD related mortality [HR 1.45 (95%CI 1.19–1.76), p = 0.0003]. Conclusion: Age at RA onset, female sex and immigration status are associated with early RA‐ILD. Patients with early RA‐ILD experience increased all‐cause and RA‐ILD related mortality after adjusting for demographics and comorbidities. We show that females, immigrants and patients diagnosed with RA at an older age, are at increased risk for early RA‐ILD (within 1‐year of RA diagnosis). Early RA‐ILD carries an increased risk for RA‐ILD related mortality, which may justify a more aggressive approach to disease monitoring and treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. The clinical frailty scale is associated with progression of fibrotic interstitial lung disease – a multicentre cohort study.

Author

Guler, Sabina A., primary, Marinescu, Daniel-Costin, additional, Cox, Gerard, additional, Durand, Celine, additional, Fisher, Jolene H., additional, Grant-Orser, Amanda, additional, Goobie, Gillian C., additional, Hambly, Nathan, additional, Johannson, Kerri A., additional, Khalil, Nasreen, additional, Kolb, Martin, additional, Lok, Stacey, additional, Macisaac, Sarah, additional, Manganas, Helene, additional, Marcoux, Veronica, additional, Morisset, Julie, additional, Scallan, Ciaran, additional, Shapera, Shane, additional, Sun, Kelly, additional, Zheng, Boyang, additional, Ryerson, Christopher J., additional, and Wong, Alyson W., additional

Published
2023
Full Text
View/download PDF

22. Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung Disease

Author

Saleem, Ferhan, primary, Ryerson, Christopher J, additional, Sarma, Nandini, additional, Johannson, Kerri, additional, Marcoux, Veronica, additional, Fisher, Jolene, additional, Assayag, Deborah, additional, Manganas, Helene, additional, Khalil, Nasreen, additional, Morisset, Julie, additional, Glaspole, Ian N., additional, Goh, Nicole, additional, Oldham, Justin M., additional, Cox, Gerard, additional, Fell, Charlene, additional, Gershon, Andrea S, additional, Halayko, Andrew, additional, Hambly, Nathan, additional, Lok, Stacey D., additional, Shapera, Shane, additional, To, Teresa, additional, Wilcox, Pearce G, additional, Wong, Alyson W., additional, Kolb, Martin, additional, and Khor, Yet H, additional

Published
2023
Full Text
View/download PDF

24. Screening for Myositis Antibodies in Idiopathic Interstitial Lung Disease

Author

Fidler, Lee, Doubelt, Irena, Kandel, Sonja, Fisher, Jolene H., Mittoo, Shikha, and Shapera, Shane

Subjects
Myositis -- Diagnosis -- Risk factors, Viral antibodies -- Usage, Antibodies -- Usage, Health
Abstract

Purpose International guidelines recommend screening for connective tissue disease (CTD) with autoantibodies when evaluating patients with idiopathic interstitial lung disease (ILD). Idiopathic inflammatory myositis comprises of a subgroup of CTD diagnosed with myositis antibodies (MA), often presenting with ILD. Our aim was to evaluate the utility of MA screening in patients with idiopathic ILD. Methods A retrospective analysis was conducted on patients referred with idiopathic ILD to a tertiary centre ILD clinic who were screened for MA. Patients with known or suspected CTD were excluded. Descriptive statistics, univariate analysis and multivariable logistic regression were used to detect associations between MA and patient characteristics. Results Of 360 patients, 165 met inclusion criteria and 44 (26.7%) were identified to have MA. Fourteen patients (8.5%) had a change in diagnosis as a result of MA screening. Multivariable logistic regression identified the presence of MA to be associated with current smoking [OR 6.87 (1.65-28.64), p = 0.008] and a diffusing capacity of < 70% predicted [OR 2.55 (1.09-5.97), p = 0.03]. In patients with a change in diagnosis due to MA screening, 3 (1.8%) underwent a surgical lung biopsy and 2 (1.2%) were previously treated with antifibrotic therapy. Conclusions Screening for MA in patients with idiopathic ILD can contribute to a change in patient diagnosis, and may prevent invasive testing and unproven use of antifibrotic therapy. These results support the addition of MA to CTD screening panels during the initial evaluation of idiopathic ILD., Author(s): Lee Fidler [sup.1] , Irena Doubelt [sup.2] , Sonja Kandel [sup.3] , Jolene H. Fisher [sup.1] , Shikha Mittoo [sup.4] , Shane Shapera [sup.1] Author Affiliations: (Aff1) 0000 0001 [...]

Published
2019
Full Text
View/download PDF

25. Organic Exposures, Radiologic Features, and Patterns in Fibrotic Interstitial Lung Disease.

Author

Lok, Stacey D., Marinescu, Daniel-Costin, Marcoux, Veronica, Kolb, Martin, Fisher, Jolene H., Shapera, Shane S., Morisset, Julie, Manganas, Hélène, Ryerson, Christopher J., and Johannson, Kerri A.

Subjects
INTERSTITIAL lung diseases, LUNGS, IDIOPATHIC pulmonary fibrosis, HYPERSENSITIVITY pneumonitis, IDIOPATHIC interstitial pneumonias, PULMONARY fibrosis
Abstract

he article focuses on the association between organic exposures and specific radiologic features in patients with fibrotic hypersensitivity pneumonitis (fHP). It investigates whether certain HRCT patterns of fHP, such as mosaic attenuation, gas trapping, and the three-density sign, are linked to identified organic exposures, validating current diagnostic guidelines for fHP.

Published
2024
Full Text
View/download PDF

26. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease

Author

Wong, Alyson W., Lee, Tae Yoon, Johannson, Kerri A., Assayag, Deborah, Morisset, Julie, Fell, Charlene D., Fisher, Jolene H., Shapera, Shane, Gershon, Andrea S., Cox, Gerard, Halayko, Andrew J., Hambly, Nathan, Manganas, Helene, Sadatsafavi, Mohsen, Wilcox, Pearce G., To, Teresa, Marcoux, Veronica, Khalil, Nasreen, Kolb, Martin, and Ryerson, Christopher J.

Published
2020
Full Text
View/download PDF

30. Treatment of rheumatoid arthritis-associated interstitial lung disease in a multi-center registry cohort

Author

Marcoux, Veronica, primary, Lok, Stacey, additional, Mondal, Prosanta, additional, Assayag, Deborah, additional, Fisher, Jolene H., additional, Shapera, Shane, additional, Morisset, Julie, additional, Manganas, Hélène, additional, Fell, Charlene D., additional, Hambly, Nathan, additional, Cox, P. Gerard, additional, Kolb, Martin, additional, Gershon, Andrea S., additional, To, Teresa, additional, Sadatsafavi, Mohsen, additional, Khalil, Nasreen, additional, Wong, Alyson W., additional, Wilcox, Pierce G., additional, Ryerson, Christopher J., additional, and Johannson, Kerri A., additional

Published
2023
Full Text
View/download PDF

32. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

Author

Solomon, Joshua J, primary, Danoff, Sonye K, additional, Woodhead, Felix A, additional, Hurwitz, Shelley, additional, Maurer, Rie, additional, Glaspole, Ian, additional, Dellaripa, Paul F, additional, Gooptu, Bibek, additional, Vassallo, Robert, additional, Cox, P Gerard, additional, Flaherty, Kevin R, additional, Adamali, Huzaifa I, additional, Gibbons, Michael A, additional, Troy, Lauren, additional, Forrest, Ian A, additional, Lasky, Joseph A, additional, Spencer, Lisa G, additional, Golden, Jeffrey, additional, Scholand, Mary Beth, additional, Chaudhuri, Nazia, additional, Perrella, Mark A, additional, Lynch, David A, additional, Chambers, Daniel C, additional, Kolb, Martin, additional, Spino, Cathie, additional, Raghu, Ganesh, additional, Goldberg, Hilary J, additional, Rosas, Ivan O, additional, Haynes-Harp, Shana, additional, Poli, Fernando, additional, Vidya, Coimbatore Sree, additional, Baron, Rebecca R., additional, Clouser, Timothy, additional, Doyle, Tracy, additional, Maeda, Anthony, additional, Highland, Kristin B., additional, Albayda, Jemima F., additional, Collins, Sarah E., additional, Suresh, Karthik S., additional, Davis, John M., additional, Limper, Andrew H., additional, Amigues, Isabel, additional, Eliopoulos, Kristina, additional, Swigris, Jeffery J., additional, Humphries, Stephen, additional, Huntwork, John C., additional, Glynn, Chris, additional, Duncan, Steve R., additional, Danila, Maria I., additional, Glassberg, Marilyn K., additional, Oberstein, Elana M., additional, Belloli, Elizabeth A., additional, Briggs, Linda, additional, Nagaraja, Vivek, additional, Cholewa, Linda, additional, DiFranco, Donna, additional, Green, Edward, additional, Liffick, Christie, additional, Naik, Tanvi, additional, Montas, Genevieve, additional, Lebiedz-Odrobina, Dorota, additional, Bissell, Reba, additional, Wener, Mark, additional, Lancaster, Lisa H., additional, Crawford, Leslie J., additional, Chan, Karmela, additional, Kaner, Robert J., additional, Morris, Alicia, additional, Wu, Xiaoping, additional, Khalidi, Nader A., additional, Ryerson, Christopher J., additional, Wong, Alyson W., additional, Fell, Charlene D., additional, LeClercq, Sharon A., additional, Hyman, Mark, additional, Shapera, Shane, additional, Mittoo, Shikha, additional, Shaffu, Shireen, additional, Gaffney, Karl, additional, Wilson, Andrew M., additional, Barratt, Shaney, additional, Gunawardena, Harsha, additional, Hoyles, Rachel K., additional, David, Joel, additional, Kewalramani, Namrata, additional, Maher, Toby M., additional, Molyneaux, Philip L., additional, Kokosi, Maria A., additional, Cates, Matthew J., additional, Mandizha, Mandizha, additional, Ashish, Abdul, additional, Chelliah, Gladstone, additional, Parfrey, Helen, additional, Thillai, Muhunthan, additional, Vila, Josephine, additional, Fletcher, Sophie V., additional, Beirne, Paul, additional, Favager, Clair, additional, Brown, Jo, additional, Dawson, Julie K., additional, Ortega, Pilar Rivera, additional, Haque, Sahena, additional, Watson, Pippa, additional, Khoo, Jun K., additional, Symons, Karen, additional, Youssef, Peter, additional, and Mackintosh, John A., additional

Published
2023
Full Text
View/download PDF

33. Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions

Author

Khor, Yet H., primary, Farooqi, Malik, additional, Hambly, Nathan, additional, Kolb, Martin, additional, Ryerson, Christopher J., additional, Assayag, Deborah, additional, Cox, Gerard, additional, Fell, Charlene D., additional, Fisher, Jolene H., additional, Gershon, Andrea S., additional, Goh, Nicole, additional, Halayko, Andrew J., additional, Johannson, Kerri A., additional, Khalil, Nasreen, additional, Lok, Stacey, additional, Manganas, Helene, additional, Marcoux, Veronica, additional, Morisset, Julie, additional, Sadatsafavi, Mohsen, additional, Shapera, Shane, additional, To, Teresa, additional, Wilcox, Pearce G., additional, and Wong, Alyson W., additional

Published
2023
Full Text
View/download PDF

34. Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease

Author

Lok, Stacey D., primary, Wong, Alyson W., additional, Khor, Yet H., additional, Ryerson, Christopher J., additional, Johannson, Kerri A., additional, Marcoux, Veronica, additional, Khalil, Nasrin, additional, Cox, Gerard, additional, Hambly, Nathan, additional, Kolb, Martin, additional, Fell, Charlene, additional, Fisher, Jolene, additional, Shapera, Shane, additional, To, Teresa, additional, Gershon, Andrea, additional, Halayko, Andrew, additional, Manganas, Hélène, additional, Morisset, Julie, additional, Assayag, Deborah, additional, Sadatsafavi, Mohsen, additional, and Wilcox, Pearce, additional

Published
2022
Full Text
View/download PDF

35. Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease

Author

Marcoux, Veronica, Khalil, Nasrin, Cox, Gerard, Hambly, Nathan, Kolb, Martin, Fell, Charlene, Fisher, Jolene, Shapera, Shane, To, Teresa, Gershon, Andrea, Halayko, Andrew, Manganas, Hélène, Morisset, Julie, Assayag, Deborah, Sadatsafavi, Mohsen, Wilcox, Pearce, Lok, Stacey D., Wong, Alyson W., Khor, Yet H., Ryerson, Christopher J., and Johannson, Kerri A.

Published
2022
Full Text
View/download PDF

36. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry

Author

Hambly, Nathan, Farooqi, M Malik, Dvorkin-Gheva, Anna, Donohoe, Kathryn, Garlick, Kristopher, Scallan, Ciaran, Chong, Sy Giin, Macisaac, Sarah, Assayag, Deborah, Johannson, Kerri A, Fell, Charlene D, Marcoux, Veronica, Manganas, Helene, Morisset, Julie, Comes, Alessia, Fisher, Jolene H, Shapera, Shane, Gershon, Andrea S, To, Teresa, Wong, Alyson W, Sadatsafavi, Mohsen, Wilcox, Pierce G, Halayko, Andrew J, Khalil, Nasreen, Cox, Gerard, Richeldi, Luca, Ryerson, Christopher J, Kolb, Martin, Richeldi, Luca (ORCID:0000-0001-8594-1448), Hambly, Nathan, Farooqi, M Malik, Dvorkin-Gheva, Anna, Donohoe, Kathryn, Garlick, Kristopher, Scallan, Ciaran, Chong, Sy Giin, Macisaac, Sarah, Assayag, Deborah, Johannson, Kerri A, Fell, Charlene D, Marcoux, Veronica, Manganas, Helene, Morisset, Julie, Comes, Alessia, Fisher, Jolene H, Shapera, Shane, Gershon, Andrea S, To, Teresa, Wong, Alyson W, Sadatsafavi, Mohsen, Wilcox, Pierce G, Halayko, Andrew J, Khalil, Nasreen, Cox, Gerard, Richeldi, Luca, Ryerson, Christopher J, Kolb, Martin, and Richeldi, Luca (ORCID:0000-0001-8594-1448)

Abstract

Rationale Progressive fibrosing interstitial lung disease (PF-ILD) is characterized by progressive physiologic, symptomatic, and/or radiographic worsening. The real-world prevalence and characteristics of PF-ILD remain uncertain. Methods Patients were enrolled from the Canadian Registry for Pulmonary Fibrosis between 2015-2020. PF-ILD was defined as a relative forced vital capacity (FVC) decline ≥10%, death, lung transplantation, or any 2 of: relative FVC decline ≥5 and <10%, worsening respiratory symptoms, or worsening fibrosis on computed tomography of the chest, all within 24 months of diagnosis. Time-to-event analysis compared progression between key diagnostic subgroups. Characteristics associated with progression were determined by multivariable regression. Results Of 2,746 patients with fibrotic ILD (mean age 65±12 years, 51% female), 1,376 (50%) met PFILD criteria in the first 24 months of follow-up. PF-ILD occurred in 427 (59%) patients with idiopathic pulmonary fibrosis (IPF), 125 (58%) with fibrotic hypersensitivity pneumonitis (HP), 281 (51%) with unclassifiable ILD (U-ILD), and 402 (45%) with connective tissue diseaseassociated ILD (CTD-ILD). Compared to IPF, time to progression was similar in patients with HP (hazard ratio [HR] 0.96, 95% confidence interval, CI 0.79-1.17), but was delayed in patients with U-ILD (HR 0.82, 95% CI 0.71-0.96) and CTD-ILD (HR 0.65, 95% CI 0.56-0.74). Background treatment varied across diagnostic subtypes with 66% of IPF patients receiving antifibrotic therapy, while immunomodulatory therapy was utilized in 49%, 61%, and 37% of patients with CHP, CTD-ILD, and U-ILD respectively. Increasing age, male sex, gastroesophageal reflux disease, and lower baseline pulmonary function were independently associated with progression. Interpretation Progression is common in patients with fibrotic ILD, and is similarly prevalent in HP and IPF. Routinely collected variables help identify patients at risk for progression and may guide the

Published
2022

37. Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease

Author

Wong, Alyson W, Khor, Yet H, Donohoe, Kathryn, Comes, Alessia, Marcoux, Veronica, Fisher, Jolene H, Johannson, Kerri A, Assayag, Deborah, Morisset, Julie, Shapera, Shane, Khalil, Nasreen, Fell, Charlene D, Manganas, Helene, Cox, Gerard, To, Teresa, Gershon, Andrea S, Hambly, Nathan, Halayko, Andrew J, Sadatsafavi, Mohsen, Wilcox, Pearce G, Kolb, Martin, Richeldi, Luca, Ryerson, Christopher J, Richeldi, Luca (ORCID:0000-0001-8594-1448), Wong, Alyson W, Khor, Yet H, Donohoe, Kathryn, Comes, Alessia, Marcoux, Veronica, Fisher, Jolene H, Johannson, Kerri A, Assayag, Deborah, Morisset, Julie, Shapera, Shane, Khalil, Nasreen, Fell, Charlene D, Manganas, Helene, Cox, Gerard, To, Teresa, Gershon, Andrea S, Hambly, Nathan, Halayko, Andrew J, Sadatsafavi, Mohsen, Wilcox, Pearce G, Kolb, Martin, Richeldi, Luca, Ryerson, Christopher J, and Richeldi, Luca (ORCID:0000-0001-8594-1448)

Published
2022

38. Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis

Author

Lee, Cathryn T., primary, Strek, Mary E., additional, Adegunsoye, Ayodeji, additional, Wong, Alyson W., additional, Assayag, Deborah, additional, Cox, Gerard, additional, Fell, Charlene D., additional, Fisher, Jolene H., additional, Gershon, Andrea S., additional, Halayko, Andrew J., additional, Hambly, Nathan, additional, Khalil, Nasreen, additional, Kolb, Martin, additional, Lok, Stacey D., additional, Manganas, Hélène, additional, Marcoux, Veronica, additional, Morisset, Julie, additional, Sadatsafavi, Mohsen, additional, Shapera, Shane, additional, To, Teresa, additional, Wilcox, Pearce, additional, Ryerson, Christopher J., additional, and Johannson, Kerri A., additional

Published
2022
Full Text
View/download PDF

39. Correlation of respiratory oscillometry with CT image analysis in a prospective cohort of idiopathic pulmonary fibrosis

Author

Wu, Joyce K Y, primary, Ma, Jin, additional, Nguyen, Lena, additional, Dehaas, Emily Leah, additional, Vasileva, Anastasiia, additional, Chang, Ehren, additional, Liang, Jady, additional, Huang, Qian Wen, additional, Cassano, Antonio, additional, Binnie, Matthew, additional, Shapera, Shane, additional, Fisher, Jolene, additional, Ryan, Clodagh M, additional, McInnis, Micheal Chad, additional, Hantos, Zoltán, additional, and Chow, Chung-Wai, additional

Published
2022
Full Text
View/download PDF

40. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry

Author

Hambly, Nathan, primary, Farooqi, M. Malik, additional, Dvorkin-Gheva, Anna, additional, Donohoe, Kathryn, additional, Garlick, Kristopher, additional, Scallan, Ciaran, additional, Chong, Sy Giin, additional, MacIsaac, Sarah, additional, Assayag, Deborah, additional, Johannson, Kerri A., additional, Fell, Charlene D., additional, Marcoux, Veronica, additional, Manganas, Helene, additional, Morisset, Julie, additional, Comes, Alessia, additional, Fisher, Jolene H., additional, Shapera, Shane, additional, Gershon, Andrea S., additional, To, Teresa, additional, Wong, Alyson W., additional, Sadatsafavi, Mohsen, additional, Wilcox, Pierce G., additional, Halayko, Andrew J., additional, Khalil, Nasreen, additional, Cox, Gerard, additional, Richeldi, Luca, additional, Ryerson, Christopher J., additional, and Kolb, Martin, additional

Published
2022
Full Text
View/download PDF

41. Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease

Author

Johannson, Kerri A., primary, Lethebe, Brendan C., additional, Assayag, Deborah, additional, Fisher, Jolene H., additional, Kolb, Martin, additional, Morisset, Julie, additional, Shapera, Shane, additional, Gershon, Andrea S., additional, Hambly, Nathan, additional, Khalil, Nasreen, additional, To, Teresa, additional, Fell, Charlene D., additional, Cox, Gerard, additional, Manganas, Hélène, additional, Halayko, Andrew J., additional, Marcoux, Veronica, additional, Sadatsafavi, Mohsen, additional, Wilcox, Pearce G., additional, Bertazzon, Stefania, additional, and Ryerson, Christopher J., additional

Published
2022
Full Text
View/download PDF

42. Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Non-IPF Fibrotic Interstitial Lung Disease

Author

Wong, Alyson W., primary, Khor, Yet H, additional, Donohoe, Kathryn, additional, Comes, Alessia, additional, Marcoux, Veronica, additional, Fisher, Jolene H, additional, Johannson, Kerri A, additional, Assayag, Deborah, additional, Morisset, Julie, additional, Shapera, Shane, additional, Khalil, Nasreen, additional, Fell, Charlene D, additional, Manganas, Helene, additional, Cox, Gerard, additional, To, Teresa, additional, Gershon, Andrea S, additional, Hambly, Nathan, additional, Halayko, Andrew J, additional, Sadatsafavi, Mohsen, additional, Wilcox, Pearce G, additional, Kolb, Martin, additional, Richeldi, Luca, additional, and Ryerson, Christopher J, additional

Published
2021
Full Text
View/download PDF

44. Treatment Initiation in Patients with Interstitial Lung Disease in Canada

Author

Assayag, Deborah, primary, Garlick, Kristopher, additional, Johannson, Kerri A., additional, Fell, Charlene D., additional, Kolb, Martin, additional, Cox, Gerard, additional, Hambly, Nathan, additional, Manganas, Helene, additional, Morisset, Julie, additional, Fisher, Jolene H., additional, Shapera, Shane, additional, Gershon, Andrea S., additional, To, Teresa, additional, Sadatsafavi, Mohsen, additional, Wilcox, Pearce G., additional, Halayko, Andrew J., additional, Khalil, Nasreen, additional, and Ryerson, Christopher J., additional

Published
2021
Full Text
View/download PDF

45. Clinical relevance of rheumatoid factor and anti‐citrullinated peptides in fibrotic interstitial lung disease.

Author

Zheng, Boyang, Donohoe, Kathryn, Hambly, Nathan, Johannson, Kerri A., Assayag, Deborah, Fisher, Jolene H., Manganas, Helene, Marcoux, Veronica, Khalil, Nasreen, Kolb, Martin, Ryerson, Christopher J., Wong, Alyson W., Lok, Stacey, Morisset, Julie, Fell, Charlene D., Shapera, Shane, Gershon, Andrea S., Cox, Gerard, Halayko, Andrew J., and Sadatsafavi, Mohsen

Subjects
IDIOPATHIC interstitial pneumonias, INTERSTITIAL lung diseases, RHEUMATOID factor, IDIOPATHIC pulmonary fibrosis, HYPERSENSITIVITY pneumonitis, CONNECTIVE tissue diseases
Abstract

Background and objective: Rheumatoid arthritis (RA) is a frequent cause of interstitial lung disease (ILD); however, the impact of rheumatoid factor and anti‐citrullinated peptide antibody seropositivity in ILD without connective tissue disease (CTD) is unclear. We examined the association of seropositivity with ILD progression, mortality and response to immunosuppression in non‐CTD ILD. Methods: A total of 1570 non‐CTD patients (with idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, interstitial pneumonia with autoimmune features or unclassifiable ILD) and 181 RA‐ILD patients were included from a prospective registry. Longitudinal forced vital capacity (FVC), transplant‐free survival and incidence of progressive fibrosing‐ILD (PF‐ILD) were compared between seronegative non‐CTD ILD (reference group), seropositive non‐CTD ILD and RA‐ILD using linear mixed‐effect and Cox proportional hazards models adjusted for age, sex, smoking pack‐years and baseline FVC. Interaction between seropositivity and immunosuppression on FVC decline was assessed in patients with ≥6 months of follow‐up before and after the treatment. Results: Two hundred and seventeen (13.8%) patients with seropositive non‐CTD ILD had similar rates of FVC decline and transplant‐free survival compared to seronegative non‐CTD ILD, but more frequently met the criteria for PF‐ILD (hazard ratio [HR] = 1.35, p = 0.004). RA‐ILD had slower FVC decline (p = 0.03), less PF‐ILD (HR = 0.75, p = 0.03) and lower likelihood of lung transplant or death (HR = 0.66, p = 0.01) compared to seronegative non‐CTD ILD. No interaction was found between seropositivity and treatment on FVC decline in non‐CTD ILD. Conclusion: Seropositivity in non‐CTD ILD was not associated with improved outcomes or treatment response, highlighting the importance of other disease features in determining prognosis and predicting response to immunosuppression. We show that rheumatoid factor and anti‐citrullinated peptide antibody are not associated with outcomes or response to immunosuppression in patients with interstitial lung diseases not due to connective tissue disease, indicating the need for future studies to test the prognostic impact of other clinical and radiological features that may predict response to therapy. See relatedEditorial [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Additional file 1 of Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease

Author

Chen, Tao, Tsai, Amy Po Yu, Hur, Seo Am, Wong, Alyson W., Sadatsafavi, Mohsen, Fisher, Jolene H., Johannson, Kerri A., Assayag, Deborah, Morisset, Julie, Shapera, Shane, Khalil, Nasreen, Fell, Charlene D., Manganas, Helene, Cox, Gerard, To, Teresa, Gershon, Andrea S., Hambly, Nathan, Halayko, Andrew J., Wilcox, Pearce G., Kolb, Martin, and Ryerson, Christopher J.

Abstract

Additional file 1: Table E1. Baseline characteristics of patients with and without 6-month follow-up. Table E2. Baseline characteristics across ILD subtypes. Table E3. Change in anchors across tertiles of change in UCSDSOBQ over 12 months. Table E4. IPF and non-IPF subgroup analysis of anchor- and distribution-based estimates of MID for UCSDSOBQ. Table E5. CTD-ILD and non-CTD-ILD subgroup analysis of anchor- and distribution-based estimates of MID for UCSDSOBQ. Table E6. Female and male subgroup analysis of anchor- and distribution-based estimates of MID for the UCSDSOBQ. Table E7. Older and younger subgroup analysis of anchor- and distribution-based estimates of MID for the UCSDSOBQ.

Published
2021
Full Text
View/download PDF

47. Validation and minimum important difference of the UCSD shortness of breath questionnaire in fibrotic interstitial lung disease

Author

Chen, Tao, primary, Tsai, Amy Po Yu, additional, Hur, Seo Am, additional, Wong, Alyson W., additional, Sadatsafavi, Mohsen, additional, Fisher, Jolene H., additional, Johannson, Kerri A., additional, Assayag, Deborah, additional, Morisset, Julie, additional, Shapera, Shane, additional, Khalil, Nasreen, additional, Fell, Charlene D., additional, Manganas, Helene, additional, Cox, Gerard, additional, To, Teresa, additional, Gershon, Andrea S., additional, Hambly, Nathan, additional, Halayko, Andrew J., additional, Wilcox, Pearce G, additional, Kolb, Martin, additional, and Ryerson, Christopher J., additional

Published
2021
Full Text
View/download PDF

48. Additional file 1 of A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease

Author

Wong, Alyson W., Lee, Tae Yoon, Johannson, Kerri A., Assayag, Deborah, Morisset, Julie, Fell, Charlene D., Fisher, Jolene H., Shapera, Shane, Gershon, Andrea S., Cox, Gerard, Halayko, Andrew J., Hambly, Nathan, Manganas, Helene, Sadatsafavi, Mohsen, Wilcox, Pearce G., To, Teresa, Marcoux, Veronica, Khalil, Nasreen, Kolb, Martin, and Ryerson, Christopher J.

Subjects
respiratory system
Abstract

Additional file 1: Table S1. Cluster composition for each ILD subtype. Table S2. Major types of connective tissue diseases in each cluster.

Published
2020
Full Text
View/download PDF

50. Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease.

Author

Wong, Alyson W., Khor, Yet H., Donohoe, Kathryn, Comes, Alessia, Marcoux, Veronica, Fisher, Jolene H., Johannson, Kerri A., Assayag, Deborah, Morisset, Julie, Shapera, Shane, Khalil, Nasreen, Fell, Charlene D., Manganas, Helene, Cox, Gerard, To, Teresa, Gershon, Andrea S., Hambly, Nathan, Halayko, Andrew J., Sadatsafavi, Mohsen, and Wilcox, Pearce G.

Subjects
IDIOPATHIC pulmonary fibrosis, AZATHIOPRINE, INTERSTITIAL lung diseases, FIBROSIS, IMMUNOSUPPRESSIVE agents
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results